title: Bee venom and its component apamin as neuroprotective agents in a Parkinson disease mouse model.
abstract: Bee venom has recently been suggested to possess beneficial effects in the treatment of Parkinson disease (PD). For instance, it has been observed that bilateral acupoint stimulation of lower hind limbs with bee venom was protective in the acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD. In particular, a specific component of bee venom, apamin, has previously been shown to have protective effects on dopaminergic neurons in vitro. However, no information regarding a potential protective action of apamin in animal models of PD is available to date. The specific goals of the present study were to (i) establish that the protective effect of bee venom for dopaminergic neurons is not restricted to acupoint stimulation, but can also be observed using a more conventional mode of administration and to (ii) demonstrate that apamin can mimic the protective effects of a bee venom treatment on dopaminergic neurons. Using the chronic mouse model of MPTP/probenecid, we show that bee venom provides sustained protection in an animal model that mimics the chronic degenerative process of PD. Apamin, however, reproduced these protective effects only partially, suggesting that other components of bee venom enhance the protective action of the peptide.
authors: Université Pierre et Marie Curie-Paris 6, UMR_S 975 - UMR 7725, Centre de Recherche en Neurosciences, ICM, Therapeutique Experimentale de la Neurodegenerescence, Paris, France.
authors: Daniel
authors: D
authors: Alvarez-Fischer
authors: Carmen
authors: C
authors: Noelker
authors: Franca
authors: F
authors: Vulinović
authors: Anne
authors: A
authors: Grünewald
authors: Caroline
authors: C
authors: Chevarin
authors: Christine
authors: C
authors: Klein
authors: Wolfgang H
authors: WH
authors: Oertel
authors: Etienne C
authors: EC
authors: Hirsch
authors: Patrick P
authors: PP
authors: Michel
authors: Andreas
authors: A
authors: Hartmann
mesh_terms: D015669:Acupuncture Points; D000818:Animals; D001030:Apamin / Q000494:pharmacology*; D001514:Bee Venoms / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D004195:Disease Models, Animal; D059290:Dopaminergic Neurons / Q000187:drug effects*; D005106:Exploratory Behavior / Q000187:drug effects; D020267:MPTP Poisoning / Q000517:prevention & control; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018696:Neuroprotective Agents / Q000494:pharmacology*; D010300:Parkinson Disease / Q000517:prevention & control*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D001514:Bee Venoms; D018696:Neuroprotective Agents; D014409:Tumor Necrosis Factor-alpha; D001030:Apamin
references: Nat Neurosci. 2005 Dec;8(12):1742-51
references: 16299504
references: J Neurosci. 2004 Jun 30;24(26):5922-30
references: 15229240
references: Parkinsonism Relat Disord. 2008;14 Suppl 2:S112-5
references: 18585085
references: Biochemistry (Mosc). 2001 Oct;66(10):1122-31
references: 11736633
references: Brain Res. 2012 Jan 6;1429:106-15
references: 22078207
references: Int J Neurosci. 2011 Apr;121(4):209-17
references: 21265705
references: J Neurosci. 2004 Jun 9;24(23):5301-6
references: 15190101
references: Biochem J. 2005 Aug 1;389(Pt 3):593-610
references: 16035954
references: Neuron. 2003 Sep 11;39(6):889-909
references: 12971891
references: Exp Neurol. 2008 Mar;210(1):182-93
references: 18053987
references: Science. 2004 May 21;304(5674):1120-2
references: 15155938
references: Physiol Behav. 2009 Aug 4;98(1-2):130-8
references: 19410592
references: Lancet Neurol. 2009 Apr;8(4):382-97
references: 19296921
references: J Ethnopharmacol. 2007 Apr 20;111(1):176-81
references: 17166679
references: Neurol Res. 2010 Feb;32 Suppl 1:88-91
references: 20034453
references: J Neurochem. 2008 Nov;107(3):701-11
references: 18761710
references: Prostaglandins Leukot Essent Fatty Acids. 2009 Nov-Dec;81(5-6):341-7
references: 19910175
references: Mov Disord. 2011 May;26(6):1072-82
references: 21626552
references: Neurosci Res. 2006 Jun;55(2):197-203
references: 16621078
references: J Neuroinflammation. 2010 Jan 14;7:4
references: 20074365
references: Exp Neurol. 2009 Sep;219(1):266-73
references: 19500570
references: J Neuroinflammation. 2011 Jun 20;8:69
references: 21682930
references: J Neurosci. 2000 Nov 15;20(22):8493-503
references: 11069957
references: J Neurosci. 2001 May 15;21(10):3443-56
references: 11331374
references: Zhongguo Yao Li Xue Bao. 1997 Jan;18(1):3-5
references: 10072885
references: FASEB J. 2011 Aug;25(8):2563-73
references: 21507900
references: J Neurochem. 2007 Apr;101(2):289-97
references: 17402966
references: Neurosci Biobehav Rev. 2004 Jan;27(8):827-39
references: 15019432
references: PLoS One. 2010 Sep 27;5(9):e12962
references: 20885945
references: Eur J Pharmacol. 1997 May 30;327(2-3):135-41
references: 9200551
references: Neuroscience. 2006;138(2):631-40
references: 16446039
references: Cell Mol Life Sci. 2008 Oct;65(20):3196-217
references: 18597044
references: Biochemistry. 1983 Apr 12;22(8):1901-6
references: 6849893
references: Neuroscience. 2001;106(3):589-601
references: 11591459
references: Neuroscience. 2012 Aug 16;217:67-76
references: 22554781
references: Acta Neuropathol. 2008 Apr;115(4):385-98
references: 18273623
references: PLoS One. 2012;7(6):e38692
references: 22719923